* current or history of a laboratory-confirmed diagnosis of sars-cov-2 infection or covid-19. * unstable current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or confound data interpretation. * immunosuppression (immunodeficiency, acquired immunodeficiency syndrome \[aids\], use of systemic steroids, use of immunosuppressants within the past 6 months prior to the first dose of study intervention, treatment for malignant tumors, other immunosuppressive therapy). * previous vaccination against sars-cov-2. * any inactivated vaccine received within 14 days prior to the first dose of study intervention. * any live vaccine received within 28 days prior to the first dose of study intervention. * immunoglobulin preparations, blood products, or a blood transfusion within 3 months prior to the first dose of study intervention. other inclusion and exclusion criteria may apply.

* current or history of a laboratory-confirmed diagnosis of sars-cov-2 infection or covid-19. * unstable current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or confound data interpretation. * immunosuppression (immunodeficiency, acquired immunodeficiency syndrome \[aids\], use of systemic steroids, use of immunosuppressants within the past 6 months prior to the first dose of study intervention, treatment for malignant tumors, other immunosuppressive therapy). * previous vaccination against sars-cov-2. * any inactivated vaccine received within 14 days prior to the first dose of study intervention. * any live vaccine received within 28 days prior to the first dose of study intervention. * immunoglobulin preparations, blood products, or a blood transfusion within 3 months prior to the first dose of study intervention. other inclusion and exclusion criteria may apply.

current or history of a laboratory-confirmed diagnosis of sars-cov-2 infection or covid-19. unstable current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or confound data interpretation. immunosuppression (immunodeficiency, acquired immunodeficiency syndrome [aids], use of systemic steroids, use of immunosuppressants within the past 6 months prior to the first dose of study intervention, treatment for malignant tumors, other immunosuppressive therapy). previous vaccination against sars-cov-2. any inactivated vaccine received within 14 days prior to the first dose of study intervention. any live vaccine received within 28 days prior to the first dose of study intervention. immunoglobulin preparations, blood products, or a blood transfusion within 3 months prior to the first dose of study intervention. other inclusion and exclusion criteria may apply.

current or history of a laboratory-confirmed diagnosis of sars-cov-2 infection or covid-19. unstable current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or confound data interpretation. immunosuppression (immunodeficiency, acquired immunodeficiency syndrome [aids], use of systemic steroids, use of immunosuppressants within the past 6 months prior to the first dose of study intervention, treatment for malignant tumors, other immunosuppressive therapy). previous vaccination against sars-cov-2. any inactivated vaccine received within 14 days prior to the first dose of study intervention. any live vaccine received within 28 days prior to the first dose of study intervention. immunoglobulin preparations, blood products, or a blood transfusion within 3 months prior to the first dose of study intervention. other inclusion and exclusion criteria may apply.